

March 23, 2004

**LISTING OF THE CLAIMS AS AMENDED**

Please cancel claims 69-90, 125-126, 128-129 and 134-146 without prejudice or admission. Please amend claims 115-120 and 127, and add new claims 148-152 as follows:

Claims 1 – 114: (Canceled)

Claim 115: (Currently Amended) An antibody comprising:

- (a) a heavy chain variable amino acid sequence having the amino acid sequence set forth in SEQ ID NO:19; and
- (b) a light chain variable amino acid sequence having the amino acid sequence set forth in SEQ ID NO:9,

wherein the antibody is capable of binding human CTLA-4.

Claim 116: (Currently Amended) An antibody comprising:

- (a) a heavy chain variable amino acid sequence having the amino acid sequence set forth in SEQ ID NO:17; and
- (b) a light chain variable amino acid sequence having the amino acid sequence set forth in SEQ ID NO:7,

wherein the antibody is capable of binding human CTLA4.

Claim 117: (Currently Amended) An antibody comprising:

- (a) a heavy chain variable amino acid sequence having the amino acid sequence set forth in SEQ ID NO:23; and
- (b) a light chain variable amino acid sequence having the amino acid sequence set forth in SEQ ID NO:13,

wherein the antibody is capable of binding human CTLA4.

Application No.: 09/644,668 Docket No.: 04280/100M321-US1

March 23, 2004

Claim 118: (Currently Amended) An antibody capable of binding human CTLA4, which antibody comprises:

- (a) a heavy chain variable region having CDR sequences set forth in SEQ ID NOS:27, 32 and 37; and
- (b) a light chain variable region having CDR sequences set forth in SEQ ID NOS:24, 29 and 35.

Claim 119: (Currently Amended) An antibody capable of binding human CTLA4, which antibody comprises:

- (a) a heavy chain variable region having CDR sequences set forth in SEQ ID NOS:27, 33 and 37; and
- (b) a light chain variable region having CDR sequences set forth in SEQ ID NOS:25, 30 and 35.

Claim 120: (Currently Amended) An antibody capable of binding human CTLA4, which antibody comprises:

- (a) a heavy chain variable region having CDR sequences set forth in SEQ ID NOS:28, 34 and 38; and
- (b) a light chain variable region having CDR sequences set forth in SEQ ID NOS:26, 31 and 36.

Claim 121: (Previously presented) An antibody capable of binding human CTLA4, which antibody comprises:

- (a) a heavy chain variable region of a human  $V_H$  3-30.3 gene; and
- (b) a light chain variable region of a human  $V_K$  A-27 gene.

Claim 122: (Previously presented) An antibody according to claim 121, wherein the antibody is capable of binding human CTLA4 with a binding affinity of about  $10^8 M^{-1}$  or greater.

Application No.: 09/644,668 Docket No.: 04280/100M321-US1

March 23, 2004

Claim 123: (Previously presented) An antibody according to claim 121, wherein the antibody is capable of binding human CTLA4 with a binding affinity of about  $10^9$  M<sup>-1</sup> or greater.

Claim 124: (Previously presented) An antibody according to claim 121, wherein the antibody inhibits binding of the human CTLA4 to B7-1 or to B7-2.

Claims 125-126: (Cancelled)

Claim 127: (Currently Amended) An antibody according to claim 121, wherein the antibody is a therapeutically-effective antibody that does not cross react with non-lymphoid tissue.

Claims 128-129: (Cancelled)

Claim 130 (Previously presented) An antibody capable of binding human CTLA4, which antibody comprises:

- (a) a heavy chain variable region of a human V<sub>H</sub> 3-33 gene; and
- (b) a light chain variable region of a human V<sub>K</sub> L-15 gene.

Claim 131 (Previously presented) An antibody according to claim 130, wherein the antibody is capable of binding human CTLA4 with a binding affinity of about  $10^8$  M<sup>-1</sup> or greater.

Claim 132 (Previously presented) An antibody according to claim 130, wherein the antibody is capable of binding human CTLA4 with a binding affinity of about  $10^9$  M<sup>-1</sup> or greater.

Claim 133 (Previously presented) An antibody according to claim 130, wherein the antibody inhibits binding of the human CTLA4 to B7-1 or to B7-2.

Application No.: 09/644,668 Docket No.: 04280/100M321-US1

March 23, 2004

Claims 134-147: (Canceled)

Claim 148: (New) An isolated human monoclonal antibody or antigen-binding portion thereof that specifically binds to human CTLA-4, wherein the antibody or antigen-binding portion thereof has a binding affinity that is about  $10^8 \text{ M}^{-1}$  or greater affinity; inhibits binding between CTLA-4 and B7-1; inhibits binding between CTLA-4 and B7-2; and competes for binding to CTLA-4 with an 11E8 antibody.

Claim 149: (New) An antibody according to claim 148, which antibody comprises:

- (a) a heavy chain variable region of a human  $V_H$  3-30.3 gene; and
- (b) a light chain variable region of a human  $V_K$  A-27 gene.

Claim 150: (New) An antibody according to claim 148 comprising:

- (a) a heavy chain variable amino acid sequence having the amino acid sequence set forth in SEQ ID NO:17; and
- (b) a light chain variable amino acid sequence having the amino acid sequence set forth in SEQ ID NO:7.

Claim 151: (New) An isolated therapeutically-effective human monoclonal antibody or antigen-binding portion thereof that specifically binds to human CTLA-4, wherein the antibody or antigen-binding portion thereof has a binding affinity that is about  $10^8 \text{ M}^{-1}$  or greater affinity and does not cross-react with non-lymphoid tissue.

Claim 152: (New) A therapeutically-effective antibody according to claim 151 comprising:

- (a) a heavy chain variable amino acid sequence having the amino acid sequence set forth in SEQ ID NO:17; and
- (b) a light chain variable amino acid sequence having the amino acid sequence set forth in SEQ ID NO:7.

Application No.: 09/644,668 Docket No.: 04280/100M321-US1